Abstract
Background: Fiberoptic bronchoscopy has developed rapidly as a routine test, especially it played an important role during the COVID-19. The suitable options for moderate sedation medications is necessary. The present study aimed to evaluate the feasibility and safety of remimazolam tosylate in geriatric patients undergoing fiberoptic bronchoscopy.
Methods This study is a single-center randomized controlled trial. A total of 105 geriatric patients undergoing fiberoptic bronchoscopy were divided into 3 groups (n=35) randomly. Group A (remimazolam group); Group B (midazolam group); in Group C (control group). Record the all patients’ vital signs and the rate of adverse events.
Results A total of 105 patients were enrolled and 97 actual patients (34 patients in group A, 30 patients in group B, and 33 patients in group C) were analyzed in the end. Compared with group C, the vital sign in group A and B are more stable at T1, T2, T3, and T4 (P<0.05).The frequency of hypertension in group A and group B was significantly lower than that in group C(P<0.05). Compared with group B, the onset time and recovery time of group A were shortened (both P<0.05). The satisfaction of patients and operators in group A and group B was higher than that in group C (P<0.05).
Conclusions In the sduty we found that intravenous injection of remazolam tosylate 0.2 mg/kg, fentanyl 0.5 μg/kg for sedation, and additional anesthesia with fentanyl 25 μg every 5 to 10 minutes if necessary is effictive and safe for geriatricpatients during fiberoptic bronchoscopy .
Trial registration:This study was registered with the Chinese clinical trial registry (ChiCTR2100047459),the Registration Date is 2021/06/19.